Moderna, Inc. (MRNA) shares surged 5.05% in Tuesday's pre-market trading session following the company's announcement of a significant regulatory milestone. The biotechnology firm has filed an application with the U.S. Food and Drug Administration (FDA) for the review of its Spikevax formula, which targets the SARS-CoV-2 variant LP.8.1.
This move demonstrates Moderna's continued efforts to adapt its COVID-19 vaccine to emerging variants, potentially positioning the company to maintain its strong presence in the global vaccine market. Investors appear to be reacting positively to this development, seeing it as a sign of Moderna's ongoing innovation and potential for future revenue streams.
In related news, Moderna also announced its upcoming participation in two major healthcare conferences: the Jefferies Global Health Care Conference on June 5th and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11th. These presentations may provide further insights into the company's pipeline and strategic direction, potentially sustaining investor interest in the coming weeks.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。